|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Taken together, we have identified ZRF1 as an important regulator of breast cancer progression that holds the potential to be explored for new treatment strategies in the future.
|
29983888 |
2018 |
|
Breast Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Moreover, we also explored the survival status of patients from the publicly available database and interestingly discover that high expression of ZRF1 decreases the survival of estrogen-positive breast cancer patients more than estrogen-negative status patients.
|
27350366 |
2016 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Tumor-associated antigens KRR1 and ZRF1 and their cognate autoantibodies could be considered as potential molecular markers of breast cancer which need to be further investigated.
|
27847402 |
2016 |
|
Breast Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
IgG antibodies directed against MPP11 were also detected in 25-50% of the sera of patients with solid tumors such as melanoma, renal cell, ovarian and breast carcinoma. mRNA expression of MPP11 was detected in 20/20 AML patients and 7/10 patients with CML.
|
12800198 |
2003 |
|
Malignant neoplasm of breast
|
0.030 |
Biomarker
|
disease |
BEFREE |
Taken together, we have identified ZRF1 as an important regulator of breast cancer progression that holds the potential to be explored for new treatment strategies in the future.
|
29983888 |
2018 |
|
Malignant neoplasm of breast
|
0.030 |
Biomarker
|
disease |
BEFREE |
Tumor-associated antigens KRR1 and ZRF1 and their cognate autoantibodies could be considered as potential molecular markers of breast cancer which need to be further investigated.
|
27847402 |
2016 |
|
Malignant neoplasm of breast
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Moreover, we also explored the survival status of patients from the publicly available database and interestingly discover that high expression of ZRF1 decreases the survival of estrogen-positive breast cancer patients more than estrogen-negative status patients.
|
27350366 |
2016 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
The sequence analysis of ZRF1 antigen SEREX clones obtained from cDNA libraries of different tumors demonstrates that they encode different protein isoforms.<i>Conclusion</i>.
|
27847402 |
2016 |
|
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
We screened the mRNA expression of tumor-associated antigens (TAAs) from the literature (fibromodulin, survivin, OFA-iLRP, BAGE, G250, MAGE1, PRAME, proteinase, syntaxin, hTERT, WT-1) and TAAs defined previously by serological analysis of cDNA expression libraries from leukemic cells (PINCH, HSJ2, MAZ, MPP11, RHAMM/CD168, NY-Ren60).
|
16773189 |
2006 |
|
Neoplasms
|
0.030 |
GeneticVariation
|
group |
BEFREE |
Thirty-eight percent of tumors examined displayed LOH/AI involving the MPP11 genomic locus.
|
11034098 |
2000 |
|
Tumor Cell Invasion
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Hence, depletion of ZRF1 results in the acquisition of metastatic behavior by facilitating the initiation of the metastatic cascade, notably for cell adhesion, migration and invasion.
|
29983888 |
2018 |
|
Tumor Cell Invasion
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
In ZRF1-overexpressing GC cells, knockdown of ZRF1 using specific siRNAs inhibited the cell proliferation, migration and invasion and induced apoptosis in a p53-dependent manner.
|
29228320 |
2018 |
|
Leukemia, Myelocytic, Acute
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
ZRF1, a recently characterized epigenetic factor involved in transcriptional regulation, is highly overexpressed in human AML, but it is not known whether it plays a role in leukemia progression.
|
24292673 |
2014 |
|
Myeloid Leukemia, Chronic
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Several LAAs are expressed in CML and therefore are candidate structures for specific immunotherapies: bcr-abl (100%), G250 (24%), hTERT (53%), MPP11 (91%), NEWREN60 (94%), PRAME (62%), Proteinase3 (71%), RHAMM/CD168 (83%), and WT1 (53%), but not BAGE, MAGE-A1, SSX2, or NY-ESO-1.
|
17157168 |
2006 |
|
Leukemia, Myelocytic, Acute
|
0.020 |
Biomarker
|
disease |
BEFREE |
Serological responses to MPP11 were observed in 7/19 (37%) of patients with acute myeloid leukemia (AML) and 6/16 (38%) of patients with chronic myeloid leukemia (CML), but not in healthy volunteers (0/20).
|
12800198 |
2003 |
|
Myeloid Leukemia, Chronic
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
IgG antibodies directed against MPP11 were also detected in 25-50% of the sera of patients with solid tumors such as melanoma, renal cell, ovarian and breast carcinoma. mRNA expression of MPP11 was detected in 20/20 AML patients and 7/10 patients with CML.
|
12800198 |
2003 |
|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
These findings suggest that ZRF1 plays a crucial role in tumor malignant potential through its overexpression and highlight its usefulness as a prognostic factor and potential therapeutic target in GC.
|
29228320 |
2018 |
|
Malignant neoplasm of stomach
|
0.010 |
Biomarker
|
disease |
BEFREE |
These findings suggest that ZRF1 plays a crucial role in tumor malignant potential through its overexpression and highlight its usefulness as a prognostic factor and potential therapeutic target in GC.
|
29228320 |
2018 |
|
Stomach Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
These findings suggest that ZRF1 plays a crucial role in tumor malignant potential through its overexpression and highlight its usefulness as a prognostic factor and potential therapeutic target in GC.
|
29228320 |
2018 |
|
Invasive Ductal Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We provide evidence that ZRF1 plays an essential role for the early metastatic events <i>in vitro</i> and acts like a tumor suppressor protein during the progression of breast invasive ductal carcinoma into a more advanced stage.
|
29983888 |
2018 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
These findings suggest that ZRF1 plays a crucial role in tumor malignant potential through its overexpression and highlight its usefulness as a prognostic factor and potential therapeutic target in GC.
|
29228320 |
2018 |
|
Mammary Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Autoantibody Response to ZRF1 and KRR1 SEREX Antigens in Patients with Breast Tumors of Different Histological Types and Grades.
|
27847402 |
2016 |
|
leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, our data reveal that ZRF1 is a key transcriptional regulator in leukemia progression and suggest that ZRF1 inhibition could be a novel strategy to be explored for AML treatment.
|
24292673 |
2014 |
|
Childhood Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, our data reveal that ZRF1 is a key transcriptional regulator in leukemia progression and suggest that ZRF1 inhibition could be a novel strategy to be explored for AML treatment.
|
24292673 |
2014 |
|
Carcinogenesis
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Thus, ZRF1 regulates the INK4-ARF locus during cellular proliferation and senescence, and alterations in ZRF1 may contribute to tumorigenesis.
|
22733129 |
2013 |